Mechanisms of Anticancer Drug Action
暂无分享,去创建一个
[1] P. Krammer,et al. Tumor Immunology , 2018, Medical Immunology.
[2] A. Hagenbeek,et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma , 2004, Leukemia.
[3] J. Tschopp,et al. The PIDDosome, a Protein Complex Implicated in Activation of Caspase-2 in Response to Genotoxic Stress , 2004, Science.
[4] E. Slee,et al. To die or not to die: how does p53 decide? , 2004, Oncogene.
[5] Boris Zhivotovsky,et al. DNA damage-induced apoptosis , 2004, Oncogene.
[6] P. Krammer,et al. Death receptors in chemotherapy and cancer , 2004, Oncogene.
[7] C. Rudin,et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Rebecca A. Ihrie,et al. Perp-etrating p53-Dependent Apoptosis , 2004, Cell cycle.
[9] A. Ballestrero,et al. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells , 2004, Clinical Cancer Research.
[10] Martin Schuler,et al. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.
[11] A. Gunasekera,et al. Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR , 2004, FEBS letters.
[12] P. Krammer,et al. Apoptosis in cancer--implications for therapy. , 2004, Seminars in oncology.
[13] K. Debatin,et al. Apoptosis pathways in cancer and cancer therapy , 2004, Cancer Immunology, Immunotherapy.
[14] D. Green,et al. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation , 2004, The Journal of cell biology.
[15] Yigong Shi,et al. Histone H1.2 as a trigger for apoptosis , 2003, Nature Structural Biology.
[16] T. Jacks,et al. Multiple response elements and differential p53 binding control Perp expression during apoptosis. , 2003, Molecular cancer research : MCR.
[17] Alexei Degterev,et al. A decade of caspases , 2003, Oncogene.
[18] K. Lauber,et al. Cyclopentenone Prostaglandins Induce Lymphocyte Apoptosis by Activating the Mitochondrial Apoptosis Pathway Independent of External Death Receptor Signaling 1 , 2003, The Journal of Immunology.
[19] Rebecca A. Ihrie,et al. Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types , 2003, Current Biology.
[20] Andreas Villunger,et al. p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.
[21] D. Green,et al. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. , 2003, Cancer cell.
[22] Kyucheol Cho,et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. , 2003, Cancer research.
[23] D. Vaux,et al. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance , 2003, Oncogene.
[24] C. Belka,et al. Guardians of cell death: the Bcl-2 family proteins. , 2003, Essays in biochemistry.
[25] Y. Tsujimoto,et al. Involvement of Histone H1.2 in Apoptosis Induced by DNA Double-Strand Breaks , 2003, Cell.
[26] D. Green,et al. p53's Believe It or Not: Lessons on Transcription-Independent Death , 2003, Journal of Clinical Immunology.
[27] C. Belka,et al. Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy. , 2003, Current medicinal chemistry. Anti-cancer agents.
[28] B. Pützer,et al. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. , 2003, Cancer research.
[29] John Calvin Reed,et al. Peptides Targeting Caspase Inhibitors* , 2003, The Journal of Biological Chemistry.
[30] B. Gusterson,et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.
[31] W. Hahn,et al. Chemosensitivity linked to p73 function. , 2003, Cancer cell.
[32] D. Green,et al. p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation , 2003, Cell Death and Differentiation.
[33] T. Soussi. p53 mutations and resistance to chemotherapy: A stab in the back for p73. , 2003, Cancer cell.
[34] Johan Hansson,et al. Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling* , 2003, The Journal of Biological Chemistry.
[35] Takashi Tsuruo,et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. , 2003, Cancer research.
[36] M. Caligiuri,et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. , 2003, Blood.
[37] K. Schulze-Osthoff,et al. Many cuts to ruin: a comprehensive update of caspase substrates , 2003, Cell Death and Differentiation.
[38] R. Larsson,et al. Overview of the clinical efficacy of investigational anticancer drugs , 2003, Journal of internal medicine.
[39] G. Gores,et al. Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ * , 2002, The Journal of Biological Chemistry.
[40] P. Scheurich,et al. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy , 2002, Apoptosis.
[41] Ximena Opitz-Araya,et al. Requirement for Caspase-2 in Stress-Induced Apoptosis Before Mitochondrial Permeabilization , 2002, Science.
[42] Sten Orrenius,et al. Caspase-2 Acts Upstream of Mitochondria to Promote Cytochromec Release during Etoposide-induced Apoptosis* , 2002, The Journal of Biological Chemistry.
[43] K. Uematsu,et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. , 2002, Molecular cancer therapeutics.
[44] Mark D. Johnson,et al. Peg3/Pw1 Is a Mediator between p53 and Bax in DNA Damage-induced Neuronal Death* , 2002, The Journal of Biological Chemistry.
[45] G. Salvesen,et al. IAP proteins: blocking the road to death's door , 2002, Nature reviews. Molecular cell biology.
[46] Kozo Nakamura,et al. p53AIP1 regulates the mitochondrial apoptotic pathway. , 2002, Cancer research.
[47] A. Strasser,et al. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins , 2002, Cell Death and Differentiation.
[48] K. Bhalla,et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. , 2002, Blood.
[49] C. Rudin,et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] Karen L. Siedlecki,et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] R. Dummer,et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. , 2002, The Journal of investigative dermatology.
[52] Judith Roth,et al. A polymorphic microsatellite that mediates induction of PIG3 by p53 , 2002, Nature Genetics.
[53] Jiandong Chen,et al. Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53* , 2002, The Journal of Biological Chemistry.
[54] J. Tschopp,et al. Defective death receptor signaling as a cause of tumor immune escape. , 2002, Seminars in cancer biology.
[55] Scott W. Lowe,et al. Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.
[56] J. Downward,et al. The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif* , 2002, The Journal of Biological Chemistry.
[57] Yuri Lazebnik,et al. Identification of Omi/HtrA2 as a Mitochondrial Apoptotic Serine Protease That Disrupts Inhibitor of Apoptosis Protein-Caspase Interaction* , 2002, The Journal of Biological Chemistry.
[58] D. Green,et al. CELL DEATH AND IMMUNE PRIVILEGE , 2002, International reviews of immunology.
[59] M. Gleave,et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] D. Altieri,et al. The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.
[61] Thierry Soussi,et al. Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.
[62] D. Green,et al. The role of Fas ligand in immune privilege , 2001, Nature Reviews Molecular Cell Biology.
[63] V. Richon,et al. Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.
[64] G. Kroemer,et al. Organelle-specific initiation of cell death pathways , 2001, Nature Cell Biology.
[65] G. Krissansen,et al. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. , 2001, Journal of the National Cancer Institute.
[66] A. Ferguson-Smith,et al. DNA methylation in genomic imprinting, development, and disease , 2001, The Journal of pathology.
[67] Z. Wang,et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.
[68] S. Kyo,et al. Telomerase activation by histone deacetylase inhibitor in normal cells. , 2001, Nucleic acids research.
[69] M. Weller,et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release , 2001, Oncogene.
[70] Xu Luo,et al. Endonuclease G is an apoptotic DNase when released from mitochondria , 2001, Nature.
[71] R. Korneluk,et al. XIAP, the guardian angel , 2001, Nature Reviews Molecular Cell Biology.
[72] K. Helin,et al. Apaf-1 is a transcriptional target for E2F and p53 , 2001, Nature Cell Biology.
[73] M. Tohyama,et al. Activation of Caspase-12, an Endoplastic Reticulum (ER) Resident Caspase, through Tumor Necrosis Factor Receptor-associated Factor 2-dependent Mechanism in Response to the ER Stress* , 2001, The Journal of Biological Chemistry.
[74] C. Belka,et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL , 2001, Oncogene.
[75] R. K Srivastava,et al. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways , 2001, Oncogene.
[76] B. Dörken,et al. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] S. S. Strom,et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.
[78] D. Banerjee. Genasense (Genta Inc). , 2001, Current opinion in investigational drugs.
[79] Lakshmi Goyal. Cell Death Inhibition Keeping Caspases in Check , 2001, Cell.
[80] P. Krammer,et al. CD95 Ligand-Expressing Tumors Are Rejected in Anti-Tumor TCR Transgenic Perforin Knockout Mice , 2001, The Journal of Immunology.
[81] G. Kroemer,et al. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis , 2001, Oncogene.
[82] K. Khanna,et al. DNA double-strand breaks: signaling, repair and the cancer connection , 2001, Nature Genetics.
[83] N. Restifo. Countering the 'counterattack' hypothesis , 2001, Nature Medicine.
[84] K. Vousden,et al. PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.
[85] K. Kinzler,et al. PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.
[86] K. Tamai,et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity , 2001, Nature Cell Biology.
[87] W. Gerald,et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.
[88] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[89] K. Kinzler,et al. Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.
[90] M. Nau,et al. Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines , 2000, Breast Cancer Research and Treatment.
[91] X. Wu,et al. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[92] B. Zhivotovsky,et al. Distinct Pathways for Stimulation of Cytochrome cRelease by Etoposide* , 2000, The Journal of Biological Chemistry.
[93] P. Krammer,et al. A Novel AP-1 Element in the CD95 Ligand Promoter Is Required for Induction of Apoptosis in Hepatocellular Carcinoma Cells upon Treatment with Anticancer Drugs , 2000, Molecular and Cellular Biology.
[94] D. Kufe,et al. XIAP Regulates DNA Damage-induced Apoptosis Downstream of Caspase-9 Cleavage* , 2000, The Journal of Biological Chemistry.
[95] A. Wyllie,et al. Defying death after DNA damage , 2000, Nature.
[96] F. Sigaux,et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia , 2000, British journal of haematology.
[97] Claus Belka,et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis , 2000, Oncogene.
[98] Yusuke Nakamura,et al. p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53 , 2000, Cell.
[99] I. Bechmann,et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) , 2000, The Lancet.
[100] Yunping Lin,et al. Pidd, a new death-domain–containing protein, is induced by p53 and promotes apoptosis , 2000, Nature Genetics.
[101] John Calvin Reed,et al. BIRinging Chromosomes through Cell Division—And Survivin' the Experience , 2000, Cell.
[102] B. Dörken,et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo , 2000, Leukemia.
[103] I. Herr,et al. Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-α , 2000, Oncogene.
[104] John Calvin Reed,et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. , 2000, Science.
[105] Xiaodong Wang,et al. Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.
[106] D. Green. Apoptotic Pathways Paper Wraps Stone Blunts Scissors , 2000, Cell.
[107] Robert L Moritz,et al. Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.
[108] E. Slee,et al. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release , 2000, Cell Death and Differentiation.
[109] N D Marchenko,et al. Death Signal-induced Localization of p53 Protein to Mitochondria , 2000, The Journal of Biological Chemistry.
[110] T. Taniguchi,et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.
[111] D. Cunningham,et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] N. Restifo. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape , 2000, Nature Medicine.
[113] Guido Kroemer,et al. Mitochondrial control of cell death , 2000, Nature Medicine.
[114] S. Strom,et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.
[115] J C Reed,et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[116] F. Behm,et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.
[117] W. Earnshaw,et al. Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.
[118] V. Kidd,et al. Caspase-8 Activation and Bid Cleavage Contribute to MCF7 Cellular Execution in a Caspase-3-dependent Manner during Staurosporine-mediated Apoptosis* , 2000, The Journal of Biological Chemistry.
[119] W. El-Deiry,et al. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.
[120] S. Lowe,et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. , 2000, Genes & development.
[121] K. Bhalla,et al. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. , 2000, Cancer research.
[122] D. Green,et al. p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release* , 2000, The Journal of Biological Chemistry.
[123] P. Krammer,et al. Tumor counterattack – concept and reality , 2000, European journal of immunology.
[124] D. Bowtell,et al. Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[125] A. Chinnaiyan,et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[126] W. Cavenee,et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.
[127] Junying Yuan,et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β , 2000, Nature.
[128] A. Strasser,et al. Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling Implications for Cancer Therapy , 2000 .
[129] B. Gliniak,et al. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. , 1999, Cancer research.
[130] E. Slee,et al. Serial killers: ordering caspase activation events in apoptosis , 1999, Cell Death and Differentiation.
[131] S. Fulda,et al. Cytotoxic drugs and the CD95 pathway , 1999, Leukemia.
[132] M. Weller,et al. Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells , 1999, Oncogene.
[133] B. Joseph,et al. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. , 1999, Biochemical and biophysical research communications.
[134] G. Cohen,et al. Caspase Activation Involves the Formation of the Aposome, a Large (∼700 kDa) Caspase-activating Complex* , 1999, The Journal of Biological Chemistry.
[135] A. Strasser,et al. The great escape: Is immune evasion required for tumor progression? , 1999, Nature Medicine.
[136] S. Fulda,et al. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[137] D. Lawrence,et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.
[138] G. Núñez,et al. Role of cytochrome c and dATP/ATP hydrolysis in Apaf‐1‐mediated caspase‐9 activation and apoptosis , 1999, The EMBO journal.
[139] W. Dalton,et al. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. , 1999, Blood.
[140] K. Schulze-Osthoff,et al. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. , 1999, Immunity.
[141] B. Dörken,et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] I. H. Engels,et al. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. , 1999, Cancer research.
[143] I. H. Engels,et al. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. , 1999, Blood.
[144] S. Lowe,et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.
[145] E. Solary,et al. STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. , 1999, Biochemical and biophysical research communications.
[146] E. Solary,et al. Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs* , 1999, The Journal of Biological Chemistry.
[147] F. Shanahan,et al. Fas counter-attack–the best form of tumor defense? , 1999, Nature Medicine.
[148] Ruedi Aebersold,et al. Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.
[149] J C Reed,et al. IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.
[150] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[151] Emad S. Alnemri,et al. Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.
[152] D. Israeli,et al. p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.
[153] J P Luzio,et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. , 1998, Science.
[154] M. Peter,et al. Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells , 1998, Cell Death and Differentiation.
[155] G. Kroemer,et al. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. , 1998, Cancer research.
[156] T. Mak,et al. Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development , 1998, Cell.
[157] D. Ferrari,et al. Differential Regulation and ATP Requirement for Caspase-8 and Caspase-3 Activation during CD95- and Anticancer Drug–induced Apoptosis , 1998, The Journal of experimental medicine.
[158] N. D’alessandro,et al. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis , 1998, Cell Death and Differentiation.
[159] Y. Lazebnik,et al. Caspases: enemies within. , 1998, Science.
[160] S. Cory,et al. The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.
[161] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[162] Xiaodong Wang,et al. Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.
[163] L. Bracco,et al. The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.
[164] José Luis de la Pompa,et al. Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo , 1998, Cell.
[165] J. Beckmann,et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. , 1998, Immunity.
[166] D. Ferrari,et al. Apoptosis signaling by death receptors. , 1998, European journal of biochemistry.
[167] S. Srinivasula,et al. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. , 1998, Molecular cell.
[168] C. Brady,et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.
[169] V. Cryns,et al. Proteases to die for. , 1998, Genes & development.
[170] John Calvin Reed. Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[171] D. Haines,et al. mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells , 1998, Oncogene.
[172] M. Manfait,et al. Resistance to apoptosis induced by topoisomerase I inhibitors in multidrug-resistant HL60 leukemic cells. , 1998, Biochemical and biophysical research communications.
[173] Alan G. Porter,et al. Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis* , 1998, The Journal of Biological Chemistry.
[174] S. Fulda,et al. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.
[175] D. Altieri,et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma , 1998, The Lancet.
[176] D. Goeddel,et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.
[177] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[178] D. Green,et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.
[179] R. Siegel,et al. Membrane Oligomerization and Cleavage Activates the Caspase-8 (FLICE/MACHα1) Death Signal* , 1998, The Journal of Biological Chemistry.
[180] Brent R. Stockwell,et al. An Induced Proximity Model for Caspase-8 Activation* , 1998, The Journal of Biological Chemistry.
[181] S. Nagata,et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.
[182] Y. Nakamura,et al. Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. , 1997, Biochemical and biophysical research communications.
[183] E. Nabel,et al. Gene transfer of Fas ligand induces tumor regression in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[184] M. Martínez-Lorenzo,et al. Doxorubicin‐induced apoptosis in human T‐cell leukemia is mediated by caspase‐3 activation in a Fas‐independent way , 1997, FEBS letters.
[185] S. Srinivasula,et al. Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.
[186] H. Blau,et al. Immune response and myoblasts that express Fas ligand. , 1997, Science.
[187] M. Peter,et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. , 1997, Cancer research.
[188] I. Herr,et al. Activation of CD95 (APO‐1/Fas) signaling by ceramide mediates cancer therapy‐induced apoptosis , 1997, The EMBO journal.
[189] I. Herr,et al. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). , 1997, Blood.
[190] K. Kinzler,et al. A model for p53-induced apoptosis , 1997, Nature.
[191] I. Herr,et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. , 1997, Cancer research.
[192] Yusuke Nakamura,et al. GML sensitizes cancer cells to Taxol by induction of apoptosis , 1997, Oncogene.
[193] R. Greil,et al. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. , 1997, Cancer research.
[194] Y. Goltsev,et al. CASH, a Novel Caspase Homologue with Death Effector Domains* , 1997, The Journal of Biological Chemistry.
[195] Y. Nakamura,et al. Cloning of P2XM, a novel human P2X receptor gene regulated by p53. , 1997, Cancer research.
[196] W. Earnshaw,et al. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. , 1997, Blood.
[197] S. Srinivasula,et al. FLAME-1, a Novel FADD-like Anti-apoptotic Molecule That Regulates Fas/TNFR1-induced Apoptosis* , 1997, The Journal of Biological Chemistry.
[198] J. Houghton,et al. Thymineless death in colon carcinoma cells is mediated via fas signaling. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[199] D. Fabbro,et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. , 1997, Journal of the National Cancer Institute.
[200] D. Israeli,et al. A novel p53‐inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis , 1997, The EMBO journal.
[201] Margot Thome,et al. Inhibition of death receptor signals by cellular FLIP , 1997, Nature.
[202] R. Greil,et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. , 1997, Blood.
[203] K. A. McKenna,et al. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. , 1997, Cancer research.
[204] D. Hanahan,et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction , 1997, Nature Medicine.
[205] R. Weichselbaum,et al. Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[206] K. Isselbacher,et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[207] D. Cunningham,et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma , 1997, The Lancet.
[208] Xiaodong Wang,et al. DFF, a Heterodimeric Protein That Functions Downstream of Caspase-3 to Trigger DNA Fragmentation during Apoptosis , 1997, Cell.
[209] D. Vaux,et al. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[210] Mi-Ock Lee,et al. Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP‐TF and their heterodimerization , 1997, The EMBO journal.
[211] Erwin G. Van Meir,et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.
[212] D. Green,et al. Human lung carcinomas express Fas ligand. , 1997, Cancer research.
[213] Dean P. Jones,et al. Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.
[214] D. Green,et al. The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.
[215] P. Galle,et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.
[216] P. Galle,et al. Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.
[217] A. Levine,et al. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.
[218] J. Tschopp,et al. Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.
[219] Y. Nakamura,et al. Isolation of a novel GPI-anchored gene specifically regulated by p53; correlation between its expression and anti-cancer drug sensitivity. , 1996, Oncogene.
[220] F. Shanahan,et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.
[221] D. Green,et al. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. , 1996, Immunity.
[222] I. Herr,et al. Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.
[223] A. H. Drummond,et al. Fas ligand in human serum , 1996, Nature Medicine.
[224] A. Strasser,et al. Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.
[225] D. Green,et al. Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.
[226] D. Bellgrau,et al. A role for CD95 ligand in preventing graft rejection , 1995, Nature.
[227] C. Rudin,et al. Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.
[228] B. Dörken,et al. Expression of the bcl‐2 gene family in normal and malignant breast tissue: Low bax‐α expression in tumor cells correlates with resistance towards apoptosis , 1995, International journal of cancer.
[229] D. Thorley-Lawson,et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.
[230] P. Krammer,et al. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.
[231] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[232] D. Housman,et al. p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.
[233] T. Jacks,et al. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.
[234] P. Johnson,et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. , 1994, Oncogene.
[235] K. Kinzler,et al. p53 tagged sites from human genomic DNA. , 1994, Human molecular genetics.
[236] John Calvin Reed,et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.
[237] C. Croce,et al. Down-regulation of bcl-2 by p53 in breast cancer cells. , 1994, Cancer research.
[238] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[239] J. Magaud,et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.
[240] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[241] Scott W. Lowe,et al. p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.
[242] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[243] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[244] G. Williams,et al. The anti-cancer drug etoposide can induce caspase-8 processing and apoptosis in the absence of CD95 receptor-ligand interaction , 2004, Apoptosis.
[245] D. Altieri. Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.
[246] D. Altieri. Survivin and apoptosis control. , 2003, Advances in cancer research.
[247] A. Ashkenazi,et al. Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.
[248] V. Mikhail,et al. MINI REVIEW P53: AN UBIQUITOUS TARGET OF ANTICANCER DRUGS , 2002 .
[249] Michael Weller,et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.
[250] S. Srinivasula,et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity , 2002, Cell Death and Differentiation.
[251] P. Krammer,et al. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. , 2001, Cancer research.
[252] B. Vanderhyden,et al. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. , 2001, Endocrinology.
[253] K. Schulze-Osthoff,et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. , 2001, Blood.
[254] A. Thor,et al. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. , 2001, Cancer research.
[255] Jean-Claude Martinou,et al. Breaking the mitochondrial barrier , 2001, Nature Reviews Molecular Cell Biology.
[256] Y. Nakamura,et al. The role of p53-target genes in human cancer. , 2000, Critical reviews in oncology/hematology.
[257] S. Fulda,et al. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. , 2000, Blood.
[258] Aris Persidis,et al. Cancer multidrug resistance , 1999, Nature Biotechnology.
[259] A. Strasser,et al. Does "death receptor" signaling play a role in tumorigenesis and cancer therapy? , 1998, Oncology research.
[260] I. Krantz,et al. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.
[261] S. Rosenberg,et al. implications for cancer therapy , 1996 .